Skip to main content
Clinical Trials/ACTRN12609000259246
ACTRN12609000259246
Completed
Phase 3

A double-blind randomised controlled study of the anti-inflammatory effects of azithromycin 250mg daily for 12 weeks in adults with symptomatic neutrophilic airway disease

Hunter New England Area Health Service0 sites40 target enrollmentMay 13, 2009

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Asthma
Sponsor
Hunter New England Area Health Service
Enrollment
40
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 13, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Symptomatic stable asthma or Chronic Obstructive Pulmonary Disease (COPD), increased sputum neutrophils.

Exclusion Criteria

  • Hypersensitivity to macrolides, other respiratory disease, taking macrolide, tetracycline, antibiotic or oral corticosteroid in past month, taking antacid treatment, taking medication that prolongs the heart's corrected QT interval (QTc), current smoking, pregnancy, impaired liver function.

Outcomes

Primary Outcomes

Not specified

Similar Trials